PubMed · 2016 · 10 citations · 13 references
Open access
MedicineMolecular BiologyOncologyCancer PreventionMolecular OncologyNeoplasiaCancer BiomarkersCancer Molecular DiagnosticsCancer Molecular PathologyPancreatic CancerPancreatic PathologyTumor MarkersCyst Fluid AnalysisCyst Fluid CytologyMalignant ProgressionPancreatic Cancer DetectionPancreatic Cystic LesionsTumor Biomarker Discovery
Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre)malignant pancreatic lesions.
13
Soluble normal and mutated DNA sequences from single-copy genes in human blood.
George D. Sorenson, Donna M. Pribish, Frank H. Valone et al. · PubMed · 1994 · 522 citations
Cell-Free DNA in Human Blood Plasma
Mary Beth Giacona, George C. Ruben, Kenneth A. Iczkowski et al. · Pancreas · 1998 · 379 citations